1h Free Analyst Time
The cancer therapies market in europe is forecasted to grow by USD 31.24 billion during 2025-2030, accelerating at a CAGR of 6.5% during the forecast period. The report on the cancer therapies market in europe provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing cancer burden across aging population base, advancing precision medicine adoption supported by biomarker-guided treatment selection, growing investment in oncology drug research and clinical development.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
The cancer therapies market in europe is segmented as below:
By Type
- Chemotherapy
- Targeted therapy
- Immunotherapy
- Others
By Indication
- Breast cancer
- Lung cancer
- Colorectal cancer
- Prostate cancer
- Others
By End-User
- Hospitals
- Specialty clinics
- Others
Geography
- Europe
- Germany
- UK
- France
- Italy
The report on the cancer therapies market in europe covers the following areas:
- Cancer therapies market in europe sizing
- Cancer therapies market in europe forecast
- Cancer therapies market in europe industry analysis
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Country Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Type
- Executive Summary - Chart on Market Segmentation by Indication
- Executive Summary - Chart on Market Segmentation by End-user
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Market Analysis
2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Overview on criticality of inputs and factors of differentiation
- Overview on factors of disruption
- Impact of drivers and challenges in 2025 and 2030
3 Market Landscape
3.1 Market ecosystem
- Chart on Parent Market
- Data Table on - Parent Market
- Chart on Market characteristics analysis
- Chart on Value chain analysis
4 Market Sizing
4.1 Market definition
4.4 Market outlook: Forecast for 2025-2030
- Data Table on Offerings of companies included in the market definition
- Market segments
4.4 Market outlook: Forecast for 2025-2030
- Chart on Europe - Market size and forecast 2025-2030 ($ million)
- Data Table on Regional - Market size and forecast 2025-2030 ($ million)
- Chart on Europe: Year-over-year growth 2025-2030 (%)
- Data Table on Regional - Market size and forecast 2025-2030 ($ million)
5 Historic Market Size
5.1 Cancer Therapies Market in Europe 2020 - 2024
- Historic Market Size - Data Table on Cancer Therapies Market in Europe 2020 - 2024 ($ million)
- Historic Market Size - Type Segment 2020 - 2024 ($ million)
- Historic Market Size - Indication Segment 2020 - 2024 ($ million)
- Historic Market Size - End-user Segment 2020 - 2024 ($ million)
- Historic Market Size - Geography Segment 2020 - 2024 ($ million)
6 Qualitative Analysis
6.1 Impact of AI on cancer therapies market in Europe
6.2 Impact of geopolitical conflicts on cancer therapies market in Europe
6.2 Impact of geopolitical conflicts on cancer therapies market in Europe
7 Five Forces Analysis
7.1 Five forces summary
- Five forces analysis - Comparison between 2025 and 2030
- Bargaining power of buyers - Impact of key factors 2025 and 2030
- Bargaining power of suppliers - Impact of key factors in 2025 and 2030
- Threat of new entrants - Impact of key factors in 2025 and 2030
- Threat of substitutes - Impact of key factors in 2025 and 2030
- Threat of rivalry - Impact of key factors in 2025 and 2030
- Chart on Market condition - Five forces 2025 and 2030
8 Market Segmentation by Type
8.1 Market segments
- Chart on Type - Market share 2025-2030 (%)
- Data Table on Type - Market share 2025-2030 (%)
- Chart on Comparison by Type
- Data Table on Comparison by Type
- Chart on Chemotherapy - Market size and forecast 2025-2030 ($ million)
- Data Table on Chemotherapy - Market size and forecast 2025-2030 ($ million)
- Chart on Chemotherapy - Year-over-year growth 2025-2030 (%)
- Data Table on Chemotherapy - Year-over-year growth 2025-2030 (%)
- Chart on Targeted therapy - Market size and forecast 2025-2030 ($ million)
- Data Table on Targeted therapy - Market size and forecast 2025-2030 ($ million)
- Chart on Targeted therapy - Year-over-year growth 2025-2030 (%)
- Data Table on Targeted therapy - Year-over-year growth 2025-2030 (%)
- Chart on Immunotherapy - Market size and forecast 2025-2030 ($ million)
- Data Table on Immunotherapy - Market size and forecast 2025-2030 ($ million)
- Chart on Immunotherapy - Year-over-year growth 2025-2030 (%)
- Data Table on Immunotherapy - Year-over-year growth 2025-2030 (%)
- Chart on Others - Market size and forecast 2025-2030 ($ million)
- Data Table on Others - Market size and forecast 2025-2030 ($ million)
- Chart on Others - Year-over-year growth 2025-2030 (%)
- Data Table on Others - Year-over-year growth 2025-2030 (%)
- Market opportunity by Type ($ million)
- Data Table on Market opportunity by Type ($ million)
9 Market Segmentation by Indication
9.1 Market segments
- Chart on Indication - Market share 2025-2030 (%)
- Data Table on Indication - Market share 2025-2030 (%)
- Chart on Comparison by Indication
- Data Table on Comparison by Indication
- Chart on Breast cancer - Market size and forecast 2025-2030 ($ million)
- Data Table on Breast cancer - Market size and forecast 2025-2030 ($ million)
- Chart on Breast cancer - Year-over-year growth 2025-2030 (%)
- Data Table on Breast cancer - Year-over-year growth 2025-2030 (%)
- Chart on Lung cancer - Market size and forecast 2025-2030 ($ million)
- Data Table on Lung cancer - Market size and forecast 2025-2030 ($ million)
- Chart on Lung cancer - Year-over-year growth 2025-2030 (%)
- Data Table on Lung cancer - Year-over-year growth 2025-2030 (%)
- Chart on Colorectal cancer - Market size and forecast 2025-2030 ($ million)
- Data Table on Colorectal cancer - Market size and forecast 2025-2030 ($ million)
- Chart on Colorectal cancer - Year-over-year growth 2025-2030 (%)
- Data Table on Colorectal cancer - Year-over-year growth 2025-2030 (%)
- Chart on Prostate cancer - Market size and forecast 2025-2030 ($ million)
- Data Table on Prostate cancer - Market size and forecast 2025-2030 ($ million)
- Chart on Prostate cancer - Year-over-year growth 2025-2030 (%)
- Data Table on Prostate cancer - Year-over-year growth 2025-2030 (%)
- Chart on Others - Market size and forecast 2025-2030 ($ million)
- Data Table on Others - Market size and forecast 2025-2030 ($ million)
- Chart on Others - Year-over-year growth 2025-2030 (%)
- Data Table on Others - Year-over-year growth 2025-2030 (%)
- Market opportunity by Indication ($ million)
- Data Table on Market opportunity by Indication ($ million)
10 Market Segmentation by End-user
10.1 Market segments
- Chart on End-user - Market share 2025-2030 (%)
- Data Table on End-user - Market share 2025-2030 (%)
- Chart on Comparison by End-user
- Data Table on Comparison by End-user
- Chart on Hospitals - Market size and forecast 2025-2030 ($ million)
- Data Table on Hospitals - Market size and forecast 2025-2030 ($ million)
- Chart on Hospitals - Year-over-year growth 2025-2030 (%)
- Data Table on Hospitals - Year-over-year growth 2025-2030 (%)
- Chart on Specialty clinics - Market size and forecast 2025-2030 ($ million)
- Data Table on Specialty clinics - Market size and forecast 2025-2030 ($ million)
- Chart on Specialty clinics - Year-over-year growth 2025-2030 (%)
- Data Table on Specialty clinics - Year-over-year growth 2025-2030 (%)
- Chart on Others - Market size and forecast 2025-2030 ($ million)
- Data Table on Others - Market size and forecast 2025-2030 ($ million)
- Chart on Others - Year-over-year growth 2025-2030 (%)
- Data Table on Others - Year-over-year growth 2025-2030 (%)
- Market opportunity by End-user ($ million)
- Data Table on Market opportunity by End-user ($ million)
11 Customer Landscape
11.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Geographic Landscape
12.1 Geographic segmentation
- Chart on Market share by geography - 2025-2030 (%)
- Data Table on Market share by geography - 2025-2030 (%)
- Chart on Geographic comparison
- Data Table on Geographic comparison
- Chart on Germany - Market size and forecast 2025-2030 ($ million)
- Data Table on Germany - Market size and forecast 2025-2030 ($ million)
- Chart on Germany - Year-over-year growth 2025-2030 (%)
- Data Table on Germany - Year-over-year growth 2025-2030 (%)
- Chart on UK - Market size and forecast 2025-2030 ($ million)
- Data Table on UK - Market size and forecast 2025-2030 ($ million)
- Chart on UK - Year-over-year growth 2025-2030 (%)
- Data Table on UK - Year-over-year growth 2025-2030 (%)
- Chart on France - Market size and forecast 2025-2030 ($ million)
- Data Table on France - Market size and forecast 2025-2030 ($ million)
- Chart on France - Year-over-year growth 2025-2030 (%)
- Data Table on France - Year-over-year growth 2025-2030 (%)
- Chart on Italy - Market size and forecast 2025-2030 ($ million)
- Data Table on Italy - Market size and forecast 2025-2030 ($ million)
- Chart on Italy - Year-over-year growth 2025-2030 (%)
- Data Table on Italy - Year-over-year growth 2025-2030 (%)
- Chart on Rest of Europe - Market size and forecast 2025-2030 ($ million)
- Data Table on Rest of Europe - Market size and forecast 2025-2030 ($ million)
- Chart on Rest of Europe - Year-over-year growth 2025-2030 (%)
- Data Table on Rest of Europe - Year-over-year growth 2025-2030 (%)
- Market opportunity by geography ($ million)
- Data Table on Market opportunity by geography ($ million)
13 Drivers, Challenges, and Opportunity
13.1 Market drivers
- Increasing cancer burden across aging population base
- Advancing precision medicine adoption supported by biomarker-guided treatment selection
- Growing investment in oncology drug research and clinical development
- High clinical development failure rates in oncology pipelines
- Stringent reimbursement and health technology assessment requirements across Europe
- Manufacturing complexity for advanced biologic and cell-based therapies
- Impact of drivers and challenges in 2025 and 2030
- Expanding use of AI-enabled platforms in oncology discovery and treatment planning
- Increasing shift toward combination therapy development strategies
- Evolving integration of real-world evidence into oncology treatment evaluation
14 Competitive Landscape
14.1 Overview
14.2 Competitive Landscape
14.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- Overview on factors of disruption
- Impact of key risks on business
15 Competitive Analysis
15.1 Companies profiled
- Companies covered
- Company ranking index
- Matrix on companies position and classification
- AbbVie Inc. - Overview
- AbbVie Inc. - Business segments
- AbbVie Inc. - Key news
- AbbVie Inc. - Key offerings
- AbbVie Inc. - Segment focus
- SWOT
- Amgen Inc. - Overview
- Amgen Inc. - Product / Service
- Amgen Inc. - Key news
- Amgen Inc. - Key offerings
- SWOT
- AstraZeneca Plc - Overview
- AstraZeneca Plc - Business segments
- AstraZeneca Plc - Key news
- AstraZeneca Plc - Key offerings
- AstraZeneca Plc - Segment focus
- SWOT
- Bayer AG - Overview
- Bayer AG - Business segments
- Bayer AG - Key news
- Bayer AG - Key offerings
- Bayer AG - Segment focus
- SWOT
- Eli Lilly and Co. - Overview
- Eli Lilly and Co. - Product / Service
- Eli Lilly and Co. - Key news
- Eli Lilly and Co. - Key offerings
- SWOT
- F. Hoffmann La Roche Ltd. - Overview
- F. Hoffmann La Roche Ltd. - Business segments
- F. Hoffmann La Roche Ltd. - Key news
- F. Hoffmann La Roche Ltd. - Key offerings
- F. Hoffmann La Roche Ltd. - Segment focus
- SWOT
- Gilead Sciences Inc. - Overview
- Gilead Sciences Inc. - Business segments
- Gilead Sciences Inc. - Key news
- Gilead Sciences Inc. - Key offerings
- Gilead Sciences Inc. - Segment focus
- SWOT
- GlaxoSmithKline Plc - Overview
- GlaxoSmithKline Plc - Business segments
- GlaxoSmithKline Plc - Key news
- GlaxoSmithKline Plc - Key offerings
- GlaxoSmithKline Plc - Segment focus
- SWOT
- Ipsen Pharma - Overview
- Ipsen Pharma - Business segments
- Ipsen Pharma - Key offerings
- Ipsen Pharma - Segment focus
- SWOT
- Jazz Pharmaceuticals Plc - Overview
- Jazz Pharmaceuticals Plc - Product / Service
- Jazz Pharmaceuticals Plc - Key news
- Jazz Pharmaceuticals Plc - Key offerings
- SWOT
- Johnson and Johnson - Overview
- Johnson and Johnson - Business segments
- Johnson and Johnson - Key news
- Johnson and Johnson - Key offerings
- Johnson and Johnson - Segment focus
- SWOT
- Merck KGaA - Overview
- Merck KGaA - Business segments
- Merck KGaA - Key news
- Merck KGaA - Key offerings
- Merck KGaA - Segment focus
- SWOT
- Novartis AG - Overview
- Novartis AG - Business segments
- Novartis AG - Key news
- Novartis AG - Key offerings
- Novartis AG - Segment focus
- SWOT
- Pfizer Inc. - Overview
- Pfizer Inc. - Business segments
- Pfizer Inc. - Key news
- Pfizer Inc. - Key offerings
- Pfizer Inc. - Segment focus
- SWOT
- Sanofi SA - Overview
- Sanofi SA - Business segments
- Sanofi SA - Key news
- Sanofi SA - Key offerings
- Sanofi SA - Segment focus
- SWOT
16 Appendix
16.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
- Inclusions checklist
- Exclusions checklist
- Currency conversion rates for US$
- Research methodology
- Information sources
- Data validation
- Validation techniques employed for market sizing
- Data synthesis
- 360 degree market analysis
- List of abbreviations
List of Exhibits
Exhibit 1: Executive Summary - Chart on Market Overview
Exhibit 2: Executive Summary - Data Table on Market Overview
Exhibit 3: Executive Summary - Chart on Country Market Characteristics
Exhibit 4: Executive Summary - Chart on Market by Geography
Exhibit 5: Executive Summary - Chart on Market Segmentation by Type
Exhibit 6: Executive Summary - Chart on Market Segmentation by Indication
Exhibit 7: Executive Summary - Chart on Market Segmentation by End-user
Exhibit 8: Executive Summary - Chart on Incremental Growth
Exhibit 9: Executive Summary - Data Table on Incremental Growth
Exhibit 10: Executive Summary - Chart on Company Market Positioning
Exhibit 11: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibit 12: Overview on criticality of inputs and factors of differentiation
Exhibit 13: Overview on factors of disruption
Exhibit 14: Impact of drivers and challenges in 2025 and 2030
Exhibit 15: Chart on Parent Market
Exhibit 16: Data Table on - Parent Market
Exhibit 17: Chart on Market characteristics analysis
Exhibit 18: Chart on Value chain analysis
Exhibit 19: Data Table on Offerings of companies included in the market definition
Exhibit 20: Market segments
Exhibit 21: Chart on Europe - Market size and forecast 2025-2030 ($ million)
Exhibit 22: Data Table on Regional - Market size and forecast 2025-2030 ($ million)
Exhibit 23: Chart on Europe: Year-over-year growth 2025-2030 (%)
Exhibit 24: Data Table on Regional - Market size and forecast 2025-2030 ($ million)
Exhibit 25: Historic Market Size - Data Table on Cancer Therapies Market in Europe 2020 - 2024 ($ million)
Exhibit 26: Historic Market Size - Type Segment 2020 - 2024 ($ million)
Exhibit 27: Historic Market Size - Indication Segment 2020 - 2024 ($ million)
Exhibit 28: Historic Market Size - End-user Segment 2020 - 2024 ($ million)
Exhibit 29: Historic Market Size - Geography Segment 2020 - 2024 ($ million)
Exhibit 30: Five forces analysis - Comparison between 2025 and 2030
Exhibit 31: Bargaining power of buyers - Impact of key factors 2025 and 2030
Exhibit 32: Bargaining power of suppliers - Impact of key factors in 2025 and 2030
Exhibit 33: Threat of new entrants - Impact of key factors in 2025 and 2030
Exhibit 34: Threat of substitutes - Impact of key factors in 2025 and 2030
Exhibit 35: Threat of rivalry - Impact of key factors in 2025 and 2030
Exhibit 36: Chart on Market condition - Five forces 2025 and 2030
Exhibit 37: Chart on Type - Market share 2025-2030 (%)
Exhibit 38: Data Table on Type - Market share 2025-2030 (%)
Exhibit 39: Chart on Comparison by Type
Exhibit 40: Data Table on Comparison by Type
Exhibit 41: Chart on Chemotherapy - Market size and forecast 2025-2030 ($ million)
Exhibit 42: Data Table on Chemotherapy - Market size and forecast 2025-2030 ($ million)
Exhibit 43: Chart on Chemotherapy - Year-over-year growth 2025-2030 (%)
Exhibit 44: Data Table on Chemotherapy - Year-over-year growth 2025-2030 (%)
Exhibit 45: Chart on Targeted therapy - Market size and forecast 2025-2030 ($ million)
Exhibit 46: Data Table on Targeted therapy - Market size and forecast 2025-2030 ($ million)
Exhibit 47: Chart on Targeted therapy - Year-over-year growth 2025-2030 (%)
Exhibit 48: Data Table on Targeted therapy - Year-over-year growth 2025-2030 (%)
Exhibit 49: Chart on Immunotherapy - Market size and forecast 2025-2030 ($ million)
Exhibit 50: Data Table on Immunotherapy - Market size and forecast 2025-2030 ($ million)
Exhibit 51: Chart on Immunotherapy - Year-over-year growth 2025-2030 (%)
Exhibit 52: Data Table on Immunotherapy - Year-over-year growth 2025-2030 (%)
Exhibit 53: Chart on Others - Market size and forecast 2025-2030 ($ million)
Exhibit 54: Data Table on Others - Market size and forecast 2025-2030 ($ million)
Exhibit 55: Chart on Others - Year-over-year growth 2025-2030 (%)
Exhibit 56: Data Table on Others - Year-over-year growth 2025-2030 (%)
Exhibit 57: Market opportunity by Type ($ million)
Exhibit 58: Data Table on Market opportunity by Type ($ million)
Exhibit 59: Chart on Indication - Market share 2025-2030 (%)
Exhibit 60: Data Table on Indication - Market share 2025-2030 (%)
Exhibit 61: Chart on Comparison by Indication
Exhibit 62: Data Table on Comparison by Indication
Exhibit 63: Chart on Breast cancer - Market size and forecast 2025-2030 ($ million)
Exhibit 64: Data Table on Breast cancer - Market size and forecast 2025-2030 ($ million)
Exhibit 65: Chart on Breast cancer - Year-over-year growth 2025-2030 (%)
Exhibit 66: Data Table on Breast cancer - Year-over-year growth 2025-2030 (%)
Exhibit 67: Chart on Lung cancer - Market size and forecast 2025-2030 ($ million)
Exhibit 68: Data Table on Lung cancer - Market size and forecast 2025-2030 ($ million)
Exhibit 69: Chart on Lung cancer - Year-over-year growth 2025-2030 (%)
Exhibit 70: Data Table on Lung cancer - Year-over-year growth 2025-2030 (%)
Exhibit 71: Chart on Colorectal cancer - Market size and forecast 2025-2030 ($ million)
Exhibit 72: Data Table on Colorectal cancer - Market size and forecast 2025-2030 ($ million)
Exhibit 73: Chart on Colorectal cancer - Year-over-year growth 2025-2030 (%)
Exhibit 74: Data Table on Colorectal cancer - Year-over-year growth 2025-2030 (%)
Exhibit 75: Chart on Prostate cancer - Market size and forecast 2025-2030 ($ million)
Exhibit 76: Data Table on Prostate cancer - Market size and forecast 2025-2030 ($ million)
Exhibit 77: Chart on Prostate cancer - Year-over-year growth 2025-2030 (%)
Exhibit 78: Data Table on Prostate cancer - Year-over-year growth 2025-2030 (%)
Exhibit 79: Chart on Others - Market size and forecast 2025-2030 ($ million)
Exhibit 80: Data Table on Others - Market size and forecast 2025-2030 ($ million)
Exhibit 81: Chart on Others - Year-over-year growth 2025-2030 (%)
Exhibit 82: Data Table on Others - Year-over-year growth 2025-2030 (%)
Exhibit 83: Market opportunity by Indication ($ million)
Exhibit 84: Data Table on Market opportunity by Indication ($ million)
Exhibit 85: Chart on End-user - Market share 2025-2030 (%)
Exhibit 86: Data Table on End-user - Market share 2025-2030 (%)
Exhibit 87: Chart on Comparison by End-user
Exhibit 88: Data Table on Comparison by End-user
Exhibit 89: Chart on Hospitals - Market size and forecast 2025-2030 ($ million)
Exhibit 90: Data Table on Hospitals - Market size and forecast 2025-2030 ($ million)
Exhibit 91: Chart on Hospitals - Year-over-year growth 2025-2030 (%)
Exhibit 92: Data Table on Hospitals - Year-over-year growth 2025-2030 (%)
Exhibit 93: Chart on Specialty clinics - Market size and forecast 2025-2030 ($ million)
Exhibit 94: Data Table on Specialty clinics - Market size and forecast 2025-2030 ($ million)
Exhibit 95: Chart on Specialty clinics - Year-over-year growth 2025-2030 (%)
Exhibit 96: Data Table on Specialty clinics - Year-over-year growth 2025-2030 (%)
Exhibit 97: Chart on Others - Market size and forecast 2025-2030 ($ million)
Exhibit 98: Data Table on Others - Market size and forecast 2025-2030 ($ million)
Exhibit 99: Chart on Others - Year-over-year growth 2025-2030 (%)
Exhibit 100: Data Table on Others - Year-over-year growth 2025-2030 (%)
Exhibit 101: Market opportunity by End-user ($ million)
Exhibit 102: Data Table on Market opportunity by End-user ($ million)
Exhibit 103: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibit 104: Chart on Market share by geography - 2025-2030 (%)
Exhibit 105: Data Table on Market share by geography - 2025-2030 (%)
Exhibit 106: Chart on Geographic comparison
Exhibit 107: Data Table on Geographic comparison
Exhibit 108: Chart on Germany - Market size and forecast 2025-2030 ($ million)
Exhibit 109: Data Table on Germany - Market size and forecast 2025-2030 ($ million)
Exhibit 110: Chart on Germany - Year-over-year growth 2025-2030 (%)
Exhibit 111: Data Table on Germany - Year-over-year growth 2025-2030 (%)
Exhibit 112: Chart on UK - Market size and forecast 2025-2030 ($ million)
Exhibit 113: Data Table on UK - Market size and forecast 2025-2030 ($ million)
Exhibit 114: Chart on UK - Year-over-year growth 2025-2030 (%)
Exhibit 115: Data Table on UK - Year-over-year growth 2025-2030 (%)
Exhibit 116: Chart on France - Market size and forecast 2025-2030 ($ million)
Exhibit 117: Data Table on France - Market size and forecast 2025-2030 ($ million)
Exhibit 118: Chart on France - Year-over-year growth 2025-2030 (%)
Exhibit 119: Data Table on France - Year-over-year growth 2025-2030 (%)
Exhibit 120: Chart on Italy - Market size and forecast 2025-2030 ($ million)
Exhibit 121: Data Table on Italy - Market size and forecast 2025-2030 ($ million)
Exhibit 122: Chart on Italy - Year-over-year growth 2025-2030 (%)
Exhibit 123: Data Table on Italy - Year-over-year growth 2025-2030 (%)
Exhibit 124: Chart on Rest of Europe - Market size and forecast 2025-2030 ($ million)
Exhibit 125: Data Table on Rest of Europe - Market size and forecast 2025-2030 ($ million)
Exhibit 126: Chart on Rest of Europe - Year-over-year growth 2025-2030 (%)
Exhibit 127: Data Table on Rest of Europe - Year-over-year growth 2025-2030 (%)
Exhibit 128: Market opportunity by geography ($ million)
Exhibit 129: Data Table on Market opportunity by geography ($ million)
Exhibit 130: Impact of drivers and challenges in 2025 and 2030
Exhibit 131: Overview on criticality of inputs and factors of differentiation
Exhibit 132: Overview on factors of disruption
Exhibit 133: Impact of key risks on business
Exhibit 134: Companies covered
Exhibit 135: Company ranking index
Exhibit 136: Matrix on companies position and classification
Exhibit 137: AbbVie Inc. - Overview
Exhibit 138: AbbVie Inc. - Business segments
Exhibit 139: AbbVie Inc. - Key news
Exhibit 140: AbbVie Inc. - Key offerings
Exhibit 141: AbbVie Inc. - Segment focus
Exhibit 142: SWOT
Exhibit 143: Amgen Inc. - Overview
Exhibit 144: Amgen Inc. - Product / Service
Exhibit 145: Amgen Inc. - Key news
Exhibit 146: Amgen Inc. - Key offerings
Exhibit 147: SWOT
Exhibit 148: AstraZeneca Plc - Overview
Exhibit 149: AstraZeneca Plc - Business segments
Exhibit 150: AstraZeneca Plc - Key news
Exhibit 151: AstraZeneca Plc - Key offerings
Exhibit 152: AstraZeneca Plc - Segment focus
Exhibit 153: SWOT
Exhibit 154: Bayer AG - Overview
Exhibit 155: Bayer AG - Business segments
Exhibit 156: Bayer AG - Key news
Exhibit 157: Bayer AG - Key offerings
Exhibit 158: Bayer AG - Segment focus
Exhibit 159: SWOT
Exhibit 160: Eli Lilly and Co. - Overview
Exhibit 161: Eli Lilly and Co. - Product / Service
Exhibit 162: Eli Lilly and Co. - Key news
Exhibit 163: Eli Lilly and Co. - Key offerings
Exhibit 164: SWOT
Exhibit 165: F. Hoffmann La Roche Ltd. - Overview
Exhibit 166: F. Hoffmann La Roche Ltd. - Business segments
Exhibit 167: F. Hoffmann La Roche Ltd. - Key news
Exhibit 168: F. Hoffmann La Roche Ltd. - Key offerings
Exhibit 169: F. Hoffmann La Roche Ltd. - Segment focus
Exhibit 170: SWOT
Exhibit 171: Gilead Sciences Inc. - Overview
Exhibit 172: Gilead Sciences Inc. - Business segments
Exhibit 173: Gilead Sciences Inc. - Key news
Exhibit 174: Gilead Sciences Inc. - Key offerings
Exhibit 175: Gilead Sciences Inc. - Segment focus
Exhibit 176: SWOT
Exhibit 177: GlaxoSmithKline Plc - Overview
Exhibit 178: GlaxoSmithKline Plc - Business segments
Exhibit 179: GlaxoSmithKline Plc - Key news
Exhibit 180: GlaxoSmithKline Plc - Key offerings
Exhibit 181: GlaxoSmithKline Plc - Segment focus
Exhibit 182: SWOT
Exhibit 183: Ipsen Pharma - Overview
Exhibit 184: Ipsen Pharma - Business segments
Exhibit 185: Ipsen Pharma - Key offerings
Exhibit 186: Ipsen Pharma - Segment focus
Exhibit 187: SWOT
Exhibit 188: Jazz Pharmaceuticals Plc - Overview
Exhibit 189: Jazz Pharmaceuticals Plc - Product / Service
Exhibit 190: Jazz Pharmaceuticals Plc - Key news
Exhibit 191: Jazz Pharmaceuticals Plc - Key offerings
Exhibit 192: SWOT
Exhibit 193: Johnson and Johnson - Overview
Exhibit 194: Johnson and Johnson - Business segments
Exhibit 195: Johnson and Johnson - Key news
Exhibit 196: Johnson and Johnson - Key offerings
Exhibit 197: Johnson and Johnson - Segment focus
Exhibit 198: SWOT
Exhibit 199: Merck KGaA - Overview
Exhibit 200: Merck KGaA - Business segments
Exhibit 201: Merck KGaA - Key news
Exhibit 202: Merck KGaA - Key offerings
Exhibit 203: Merck KGaA - Segment focus
Exhibit 204: SWOT
Exhibit 205: Novartis AG - Overview
Exhibit 206: Novartis AG - Business segments
Exhibit 207: Novartis AG - Key news
Exhibit 208: Novartis AG - Key offerings
Exhibit 209: Novartis AG - Segment focus
Exhibit 210: SWOT
Exhibit 211: Pfizer Inc. - Overview
Exhibit 212: Pfizer Inc. - Business segments
Exhibit 213: Pfizer Inc. - Key news
Exhibit 214: Pfizer Inc. - Key offerings
Exhibit 215: Pfizer Inc. - Segment focus
Exhibit 216: SWOT
Exhibit 217: Sanofi SA - Overview
Exhibit 218: Sanofi SA - Business segments
Exhibit 219: Sanofi SA - Key news
Exhibit 220: Sanofi SA - Key offerings
Exhibit 221: Sanofi SA - Segment focus
Exhibit 222: SWOT
Exhibit 223: Inclusions checklist
Exhibit 224: Exclusions checklist
Exhibit 225: Currency conversion rates for US$
Exhibit 226: Research methodology
Exhibit 227: Information sources
Exhibit 228: Data validation
Exhibit 229: Validation techniques employed for market sizing
Exhibit 230: Data synthesis
Exhibit 231: 360 degree market analysis
Exhibit 232: List of abbreviations
Exhibit 2: Executive Summary - Data Table on Market Overview
Exhibit 3: Executive Summary - Chart on Country Market Characteristics
Exhibit 4: Executive Summary - Chart on Market by Geography
Exhibit 5: Executive Summary - Chart on Market Segmentation by Type
Exhibit 6: Executive Summary - Chart on Market Segmentation by Indication
Exhibit 7: Executive Summary - Chart on Market Segmentation by End-user
Exhibit 8: Executive Summary - Chart on Incremental Growth
Exhibit 9: Executive Summary - Data Table on Incremental Growth
Exhibit 10: Executive Summary - Chart on Company Market Positioning
Exhibit 11: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibit 12: Overview on criticality of inputs and factors of differentiation
Exhibit 13: Overview on factors of disruption
Exhibit 14: Impact of drivers and challenges in 2025 and 2030
Exhibit 15: Chart on Parent Market
Exhibit 16: Data Table on - Parent Market
Exhibit 17: Chart on Market characteristics analysis
Exhibit 18: Chart on Value chain analysis
Exhibit 19: Data Table on Offerings of companies included in the market definition
Exhibit 20: Market segments
Exhibit 21: Chart on Europe - Market size and forecast 2025-2030 ($ million)
Exhibit 22: Data Table on Regional - Market size and forecast 2025-2030 ($ million)
Exhibit 23: Chart on Europe: Year-over-year growth 2025-2030 (%)
Exhibit 24: Data Table on Regional - Market size and forecast 2025-2030 ($ million)
Exhibit 25: Historic Market Size - Data Table on Cancer Therapies Market in Europe 2020 - 2024 ($ million)
Exhibit 26: Historic Market Size - Type Segment 2020 - 2024 ($ million)
Exhibit 27: Historic Market Size - Indication Segment 2020 - 2024 ($ million)
Exhibit 28: Historic Market Size - End-user Segment 2020 - 2024 ($ million)
Exhibit 29: Historic Market Size - Geography Segment 2020 - 2024 ($ million)
Exhibit 30: Five forces analysis - Comparison between 2025 and 2030
Exhibit 31: Bargaining power of buyers - Impact of key factors 2025 and 2030
Exhibit 32: Bargaining power of suppliers - Impact of key factors in 2025 and 2030
Exhibit 33: Threat of new entrants - Impact of key factors in 2025 and 2030
Exhibit 34: Threat of substitutes - Impact of key factors in 2025 and 2030
Exhibit 35: Threat of rivalry - Impact of key factors in 2025 and 2030
Exhibit 36: Chart on Market condition - Five forces 2025 and 2030
Exhibit 37: Chart on Type - Market share 2025-2030 (%)
Exhibit 38: Data Table on Type - Market share 2025-2030 (%)
Exhibit 39: Chart on Comparison by Type
Exhibit 40: Data Table on Comparison by Type
Exhibit 41: Chart on Chemotherapy - Market size and forecast 2025-2030 ($ million)
Exhibit 42: Data Table on Chemotherapy - Market size and forecast 2025-2030 ($ million)
Exhibit 43: Chart on Chemotherapy - Year-over-year growth 2025-2030 (%)
Exhibit 44: Data Table on Chemotherapy - Year-over-year growth 2025-2030 (%)
Exhibit 45: Chart on Targeted therapy - Market size and forecast 2025-2030 ($ million)
Exhibit 46: Data Table on Targeted therapy - Market size and forecast 2025-2030 ($ million)
Exhibit 47: Chart on Targeted therapy - Year-over-year growth 2025-2030 (%)
Exhibit 48: Data Table on Targeted therapy - Year-over-year growth 2025-2030 (%)
Exhibit 49: Chart on Immunotherapy - Market size and forecast 2025-2030 ($ million)
Exhibit 50: Data Table on Immunotherapy - Market size and forecast 2025-2030 ($ million)
Exhibit 51: Chart on Immunotherapy - Year-over-year growth 2025-2030 (%)
Exhibit 52: Data Table on Immunotherapy - Year-over-year growth 2025-2030 (%)
Exhibit 53: Chart on Others - Market size and forecast 2025-2030 ($ million)
Exhibit 54: Data Table on Others - Market size and forecast 2025-2030 ($ million)
Exhibit 55: Chart on Others - Year-over-year growth 2025-2030 (%)
Exhibit 56: Data Table on Others - Year-over-year growth 2025-2030 (%)
Exhibit 57: Market opportunity by Type ($ million)
Exhibit 58: Data Table on Market opportunity by Type ($ million)
Exhibit 59: Chart on Indication - Market share 2025-2030 (%)
Exhibit 60: Data Table on Indication - Market share 2025-2030 (%)
Exhibit 61: Chart on Comparison by Indication
Exhibit 62: Data Table on Comparison by Indication
Exhibit 63: Chart on Breast cancer - Market size and forecast 2025-2030 ($ million)
Exhibit 64: Data Table on Breast cancer - Market size and forecast 2025-2030 ($ million)
Exhibit 65: Chart on Breast cancer - Year-over-year growth 2025-2030 (%)
Exhibit 66: Data Table on Breast cancer - Year-over-year growth 2025-2030 (%)
Exhibit 67: Chart on Lung cancer - Market size and forecast 2025-2030 ($ million)
Exhibit 68: Data Table on Lung cancer - Market size and forecast 2025-2030 ($ million)
Exhibit 69: Chart on Lung cancer - Year-over-year growth 2025-2030 (%)
Exhibit 70: Data Table on Lung cancer - Year-over-year growth 2025-2030 (%)
Exhibit 71: Chart on Colorectal cancer - Market size and forecast 2025-2030 ($ million)
Exhibit 72: Data Table on Colorectal cancer - Market size and forecast 2025-2030 ($ million)
Exhibit 73: Chart on Colorectal cancer - Year-over-year growth 2025-2030 (%)
Exhibit 74: Data Table on Colorectal cancer - Year-over-year growth 2025-2030 (%)
Exhibit 75: Chart on Prostate cancer - Market size and forecast 2025-2030 ($ million)
Exhibit 76: Data Table on Prostate cancer - Market size and forecast 2025-2030 ($ million)
Exhibit 77: Chart on Prostate cancer - Year-over-year growth 2025-2030 (%)
Exhibit 78: Data Table on Prostate cancer - Year-over-year growth 2025-2030 (%)
Exhibit 79: Chart on Others - Market size and forecast 2025-2030 ($ million)
Exhibit 80: Data Table on Others - Market size and forecast 2025-2030 ($ million)
Exhibit 81: Chart on Others - Year-over-year growth 2025-2030 (%)
Exhibit 82: Data Table on Others - Year-over-year growth 2025-2030 (%)
Exhibit 83: Market opportunity by Indication ($ million)
Exhibit 84: Data Table on Market opportunity by Indication ($ million)
Exhibit 85: Chart on End-user - Market share 2025-2030 (%)
Exhibit 86: Data Table on End-user - Market share 2025-2030 (%)
Exhibit 87: Chart on Comparison by End-user
Exhibit 88: Data Table on Comparison by End-user
Exhibit 89: Chart on Hospitals - Market size and forecast 2025-2030 ($ million)
Exhibit 90: Data Table on Hospitals - Market size and forecast 2025-2030 ($ million)
Exhibit 91: Chart on Hospitals - Year-over-year growth 2025-2030 (%)
Exhibit 92: Data Table on Hospitals - Year-over-year growth 2025-2030 (%)
Exhibit 93: Chart on Specialty clinics - Market size and forecast 2025-2030 ($ million)
Exhibit 94: Data Table on Specialty clinics - Market size and forecast 2025-2030 ($ million)
Exhibit 95: Chart on Specialty clinics - Year-over-year growth 2025-2030 (%)
Exhibit 96: Data Table on Specialty clinics - Year-over-year growth 2025-2030 (%)
Exhibit 97: Chart on Others - Market size and forecast 2025-2030 ($ million)
Exhibit 98: Data Table on Others - Market size and forecast 2025-2030 ($ million)
Exhibit 99: Chart on Others - Year-over-year growth 2025-2030 (%)
Exhibit 100: Data Table on Others - Year-over-year growth 2025-2030 (%)
Exhibit 101: Market opportunity by End-user ($ million)
Exhibit 102: Data Table on Market opportunity by End-user ($ million)
Exhibit 103: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibit 104: Chart on Market share by geography - 2025-2030 (%)
Exhibit 105: Data Table on Market share by geography - 2025-2030 (%)
Exhibit 106: Chart on Geographic comparison
Exhibit 107: Data Table on Geographic comparison
Exhibit 108: Chart on Germany - Market size and forecast 2025-2030 ($ million)
Exhibit 109: Data Table on Germany - Market size and forecast 2025-2030 ($ million)
Exhibit 110: Chart on Germany - Year-over-year growth 2025-2030 (%)
Exhibit 111: Data Table on Germany - Year-over-year growth 2025-2030 (%)
Exhibit 112: Chart on UK - Market size and forecast 2025-2030 ($ million)
Exhibit 113: Data Table on UK - Market size and forecast 2025-2030 ($ million)
Exhibit 114: Chart on UK - Year-over-year growth 2025-2030 (%)
Exhibit 115: Data Table on UK - Year-over-year growth 2025-2030 (%)
Exhibit 116: Chart on France - Market size and forecast 2025-2030 ($ million)
Exhibit 117: Data Table on France - Market size and forecast 2025-2030 ($ million)
Exhibit 118: Chart on France - Year-over-year growth 2025-2030 (%)
Exhibit 119: Data Table on France - Year-over-year growth 2025-2030 (%)
Exhibit 120: Chart on Italy - Market size and forecast 2025-2030 ($ million)
Exhibit 121: Data Table on Italy - Market size and forecast 2025-2030 ($ million)
Exhibit 122: Chart on Italy - Year-over-year growth 2025-2030 (%)
Exhibit 123: Data Table on Italy - Year-over-year growth 2025-2030 (%)
Exhibit 124: Chart on Rest of Europe - Market size and forecast 2025-2030 ($ million)
Exhibit 125: Data Table on Rest of Europe - Market size and forecast 2025-2030 ($ million)
Exhibit 126: Chart on Rest of Europe - Year-over-year growth 2025-2030 (%)
Exhibit 127: Data Table on Rest of Europe - Year-over-year growth 2025-2030 (%)
Exhibit 128: Market opportunity by geography ($ million)
Exhibit 129: Data Table on Market opportunity by geography ($ million)
Exhibit 130: Impact of drivers and challenges in 2025 and 2030
Exhibit 131: Overview on criticality of inputs and factors of differentiation
Exhibit 132: Overview on factors of disruption
Exhibit 133: Impact of key risks on business
Exhibit 134: Companies covered
Exhibit 135: Company ranking index
Exhibit 136: Matrix on companies position and classification
Exhibit 137: AbbVie Inc. - Overview
Exhibit 138: AbbVie Inc. - Business segments
Exhibit 139: AbbVie Inc. - Key news
Exhibit 140: AbbVie Inc. - Key offerings
Exhibit 141: AbbVie Inc. - Segment focus
Exhibit 142: SWOT
Exhibit 143: Amgen Inc. - Overview
Exhibit 144: Amgen Inc. - Product / Service
Exhibit 145: Amgen Inc. - Key news
Exhibit 146: Amgen Inc. - Key offerings
Exhibit 147: SWOT
Exhibit 148: AstraZeneca Plc - Overview
Exhibit 149: AstraZeneca Plc - Business segments
Exhibit 150: AstraZeneca Plc - Key news
Exhibit 151: AstraZeneca Plc - Key offerings
Exhibit 152: AstraZeneca Plc - Segment focus
Exhibit 153: SWOT
Exhibit 154: Bayer AG - Overview
Exhibit 155: Bayer AG - Business segments
Exhibit 156: Bayer AG - Key news
Exhibit 157: Bayer AG - Key offerings
Exhibit 158: Bayer AG - Segment focus
Exhibit 159: SWOT
Exhibit 160: Eli Lilly and Co. - Overview
Exhibit 161: Eli Lilly and Co. - Product / Service
Exhibit 162: Eli Lilly and Co. - Key news
Exhibit 163: Eli Lilly and Co. - Key offerings
Exhibit 164: SWOT
Exhibit 165: F. Hoffmann La Roche Ltd. - Overview
Exhibit 166: F. Hoffmann La Roche Ltd. - Business segments
Exhibit 167: F. Hoffmann La Roche Ltd. - Key news
Exhibit 168: F. Hoffmann La Roche Ltd. - Key offerings
Exhibit 169: F. Hoffmann La Roche Ltd. - Segment focus
Exhibit 170: SWOT
Exhibit 171: Gilead Sciences Inc. - Overview
Exhibit 172: Gilead Sciences Inc. - Business segments
Exhibit 173: Gilead Sciences Inc. - Key news
Exhibit 174: Gilead Sciences Inc. - Key offerings
Exhibit 175: Gilead Sciences Inc. - Segment focus
Exhibit 176: SWOT
Exhibit 177: GlaxoSmithKline Plc - Overview
Exhibit 178: GlaxoSmithKline Plc - Business segments
Exhibit 179: GlaxoSmithKline Plc - Key news
Exhibit 180: GlaxoSmithKline Plc - Key offerings
Exhibit 181: GlaxoSmithKline Plc - Segment focus
Exhibit 182: SWOT
Exhibit 183: Ipsen Pharma - Overview
Exhibit 184: Ipsen Pharma - Business segments
Exhibit 185: Ipsen Pharma - Key offerings
Exhibit 186: Ipsen Pharma - Segment focus
Exhibit 187: SWOT
Exhibit 188: Jazz Pharmaceuticals Plc - Overview
Exhibit 189: Jazz Pharmaceuticals Plc - Product / Service
Exhibit 190: Jazz Pharmaceuticals Plc - Key news
Exhibit 191: Jazz Pharmaceuticals Plc - Key offerings
Exhibit 192: SWOT
Exhibit 193: Johnson and Johnson - Overview
Exhibit 194: Johnson and Johnson - Business segments
Exhibit 195: Johnson and Johnson - Key news
Exhibit 196: Johnson and Johnson - Key offerings
Exhibit 197: Johnson and Johnson - Segment focus
Exhibit 198: SWOT
Exhibit 199: Merck KGaA - Overview
Exhibit 200: Merck KGaA - Business segments
Exhibit 201: Merck KGaA - Key news
Exhibit 202: Merck KGaA - Key offerings
Exhibit 203: Merck KGaA - Segment focus
Exhibit 204: SWOT
Exhibit 205: Novartis AG - Overview
Exhibit 206: Novartis AG - Business segments
Exhibit 207: Novartis AG - Key news
Exhibit 208: Novartis AG - Key offerings
Exhibit 209: Novartis AG - Segment focus
Exhibit 210: SWOT
Exhibit 211: Pfizer Inc. - Overview
Exhibit 212: Pfizer Inc. - Business segments
Exhibit 213: Pfizer Inc. - Key news
Exhibit 214: Pfizer Inc. - Key offerings
Exhibit 215: Pfizer Inc. - Segment focus
Exhibit 216: SWOT
Exhibit 217: Sanofi SA - Overview
Exhibit 218: Sanofi SA - Business segments
Exhibit 219: Sanofi SA - Key news
Exhibit 220: Sanofi SA - Key offerings
Exhibit 221: Sanofi SA - Segment focus
Exhibit 222: SWOT
Exhibit 223: Inclusions checklist
Exhibit 224: Exclusions checklist
Exhibit 225: Currency conversion rates for US$
Exhibit 226: Research methodology
Exhibit 227: Information sources
Exhibit 228: Data validation
Exhibit 229: Validation techniques employed for market sizing
Exhibit 230: Data synthesis
Exhibit 231: 360 degree market analysis
Exhibit 232: List of abbreviations
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Amgen Inc.
- Astellas Pharma Inc.
- AstraZeneca Plc
- Bayer AG
- BeiGene Ltd.
- Bristol Myers Squibb Co.
- Daiichi Sankyo Co. Ltd.
- Eisai Co. Ltd.
- Eli Lilly and Co.
- F. Hoffmann La Roche Ltd.
- Gilead Sciences Inc.
- GlaxoSmithKline Plc
- Incyte Corp.
- Ipsen Pharma
- Jazz Pharmaceuticals Plc
- Johnson and Johnson
- Merck KGaA
- Novartis AG
- Pfizer Inc.
- Sanofi SA
- Takeda Pharmaceutical Ltd.
